These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. ESH-ESC guidelines for the management of hypertension. Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B. Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473 [Abstract] [Full Text] [Related]
3. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. Ravera M, Noberasco G, Re M, Filippi A, Gallina AM, Weiss U, Cannavò R, Ravera G, Cricelli C, Deferrari G. Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656 [Abstract] [Full Text] [Related]
4. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F. Nefrologia; 2008 May; 28 Suppl 3():39-48. PubMed ID: 19018737 [Abstract] [Full Text] [Related]
8. [Arterial hypertension management in general practice in France according to global risk factors]. Amar J, Vaur L, Perret M, Bailleau C, Etienne S, Chamontin B. Arch Mal Coeur Vaiss; 2001 Aug; 94(8):843-5. PubMed ID: 11575215 [Abstract] [Full Text] [Related]
11. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA. J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [Abstract] [Full Text] [Related]
14. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial. Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, Oba K, Takeda K, Higaki J, Nakao K, CASE-J trial Group. Hypertens Res; 2009 Apr; 32(4):248-54. PubMed ID: 19347033 [Abstract] [Full Text] [Related]
15. Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes. Owen AJ, Retegan C, Rockell M, Jennings G, Reid CM. Clin Exp Pharmacol Physiol; 2009 Jul; 36(7):643-7. PubMed ID: 19076166 [Abstract] [Full Text] [Related]
16. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [Abstract] [Full Text] [Related]
17. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Weir MR. Am J Hypertens; 2005 Apr; 18(4 Pt 2):100S-105S. PubMed ID: 15837552 [Abstract] [Full Text] [Related]
18. Are there new threshold and goals in the treatment of arterial hypertension? Segura J, Ruilope LM. Eur J Clin Invest; 2012 Aug; 42(8):914-20. PubMed ID: 22404687 [Abstract] [Full Text] [Related]
20. Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK Study. Filippi A, Casula M, Tragni E, Brignoli O, Cricelli C, Poli A, Catapano AL, CHECK Study Group. Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):562-8. PubMed ID: 20308908 [Abstract] [Full Text] [Related] Page: [Next] [New Search]